increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodonehydrocodone, amoxapine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydromorphonehydromorphone and amoxapine both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and amoxapine both increase sedation. Use Caution/Monitor.hyoscyaminehyoscyamine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidoneiloperidone and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.amoxapine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and amoxapine both increase sedation. Use Caution/Monitor.imipramineamoxapine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and imipramine both increase sedation. Use Caution/Monitor.indacaterol, inhaledindacaterol, inhaled, amoxapine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.ioflupane I 123amoxapine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I123 administration.ipratropiumipratropium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isoniazidamoxapine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenolamoxapine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ketamineketamine and amoxapine both increase sedation. Use Caution/Monitor.ketotifen, ophthalmicamoxapine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophanamoxapine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatinibamoxapine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, amoxapine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.amoxapine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.lemborexantlemborexant, amoxapine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levalbuterolamoxapine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacinamoxapine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levorphanollevorphanol and amoxapine both increase sedation. Use Caution/Monitor.levothyroxinelevothyroxine increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liothyronineliothyronine increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liotrixliotrix increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.lisdexamfetamineamoxapine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.amoxapine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).lithiumamoxapine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lofepramineamoxapine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and lofepramine both increase sedation. Use Caution/Monitor.lofexidineamoxapine and lofexidine both increase sedation. Use Caution/Monitor.amoxapine decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor.loprazolamloprazolam and amoxapine both increase sedation. Use Caution/Monitor.lorazepamlorazepam and amoxapine both increase sedation. Use Caution/Monitor.lorcaserinlorcaserin will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lormetazepamlormetazepam and amoxapine both increase sedation. Use Caution/Monitor.loxapineloxapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.loxapine and amoxapine both increase sedation. Use Caution/Monitor.loxapine inhaledloxapine inhaled and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.loxapine inhaled and amoxapine both increase sedation. Use Caution/Monitor.lsdamoxapine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.lurasidoneamoxapine, lurasidone. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS effects .lurasidone and amoxapine both increase pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS effects maprotilineamoxapine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and maprotiline both increase sedation. Use Caution/Monitor.maravirocmaraviroc, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.marijuanaamoxapine and marijuana both increase sedation. Use Caution/Monitor.meclizinemeclizine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.melatoninamoxapine and melatonin both increase sedation. Use Caution/Monitor.meperidinemeperidine and amoxapine both increase sedation. Use Caution/Monitor.meprobamateamoxapine and meprobamate both increase sedation. Use Caution/Monitor.metaproterenolamoxapine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxalonemetaxalone and amoxapine both increase sedation. Use Caution/Monitor.methadoneamoxapine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.methadone and amoxapine both increase sedation. Use Caution/Monitor.methamphetamineamoxapine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methocarbamolmethocarbamol and amoxapine both increase sedation. Use Caution/Monitor.methscopolaminemethscopolamine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.methylenedioxymethamphetamineamoxapine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methylphenidateamoxapine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.methylphenidate transdermalmethylphenidate transdermal will increase the level or effect of amoxapine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. metoclopramideamoxapine and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.metoclopramide and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.midazolammidazolam and amoxapine both increase sedation. Use Caution/Monitor.midazolam intranasalmidazolam intranasal, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.midodrineamoxapine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mifepristonemifepristone, amoxapine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.mirabegronmirabegron will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.mirtazapineamoxapine and mirtazapine both increase sedation. Use Caution/Monitor.amoxapine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.modafinilamoxapine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.morphinemorphine and amoxapine both increase sedation. Use Caution/Monitor.amoxapine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.motherwortamoxapine and motherwort both increase sedation. Use Caution/Monitor.moxonidineamoxapine and moxonidine both increase sedation. Use Caution/Monitor.nabiloneamoxapine and nabilone both increase sedation. Use Caution/Monitor.nalbuphinenalbuphine and amoxapine both increase sedation. Use Caution/Monitor.naratriptannaratriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.nefopamnefopam, amoxapine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Use combination with caution.neostigmineneostigmine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.norepinephrineamoxapine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.amoxapine increases effects of norepinephrine by unknown mechanism. Use Caution/Monitor.nortriptylineamoxapine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and nortriptyline both increase sedation. Use Caution/Monitor.ofloxacinamoxapine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.olanzapineolanzapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.olanzapine and amoxapine both increase sedation. Use Caution/Monitor.olanzapine and amoxapine both increase QTc interval. Use Caution/Monitor.oliceridineamoxapine, oliceridine. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely.amoxapine increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.olodaterol inhaledamoxapine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasonabotulinumtoxinAonabotulinumtoxinA and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.opium tinctureopium tincture and amoxapine both increase sedation. Use Caution/Monitor.orphenadrineamoxapine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrine and amoxapine both increase sedation. Use Caution/Monitor.osimertinibosimertinib and amoxapine both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.oxaliplatinoxaliplatin will increase the level or effect of amoxapine by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.oxazepamoxazepam and amoxapine both increase sedation. Use Caution/Monitor.oxybutyninoxybutynin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin topicaloxybutynin topical and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin transdermaloxybutynin transdermal and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxycodoneoxycodone and amoxapine both increase sedation. Use Caution/Monitor.oxymetazoline intranasalamoxapine increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. TCAs inhibit norepinephrine uptake in adrenergic neurons, thereby increasing synaptic norepinephrine levels. Coadministration with alpha1 agonists may cause increased adrenergic receptor stimulation. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use alternant anesthetic in patients taking TCAs.oxymorphoneoxymorphone and amoxapine both increase sedation. Use Caution/Monitor.ozanimodozanimod and amoxapine both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.paliperidonepaliperidone and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.amoxapine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.paliperidone and amoxapine both increase sedation. Use Caution/Monitor.pancuroniumpancuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.papaveretumpapaveretum and amoxapine both increase sedation. Use Caution/Monitor.papaverineamoxapine and papaverine both increase sedation. Use Caution/Monitor.paroxetineamoxapine and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.pasireotideamoxapine and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.pazopanibamoxapine and pazopanib both increase QTc interval. Use Caution/Monitor.peginterferon alfa 2bpeginterferon alfa 2b, amoxapine. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.pentazocinepentazocine and amoxapine both increase sedation. Use Caution/Monitor.amoxapine and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.pentobarbitalpentobarbital and amoxapine both increase sedation. Use Caution/Monitor.perphenazineperphenazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.perphenazine and amoxapine both increase sedation. Use Caution/Monitor.phendimetrazineamoxapine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenobarbitalphenobarbital and amoxapine both increase sedation. Use Caution/Monitor.phentermineamoxapine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrineamoxapine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrine ophthalmicamoxapine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.phenylephrine POamoxapine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .pholcodineamoxapine and pholcodine both increase sedation. Use Caution/Monitor.physostigminephysostigmine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pilocarpinepilocarpine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pimozidepimozide and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.pimozide and amoxapine both increase sedation. Use Caution/Monitor.pirbuterolamoxapine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.posaconazoleamoxapine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.pralidoximepralidoxime and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.pregabalinpregabalin, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.primidoneprimidone and amoxapine both increase sedation. Use Caution/Monitor.prochlorperazineprochlorperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and amoxapine both increase QTc interval. Use Caution/Monitor.prochlorperazine and amoxapine both increase sedation. Use Caution/Monitor.promethazinepromethazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.promethazine and amoxapine both increase QTc interval. Use Caution/Monitor.promethazine and amoxapine both increase sedation. Use Caution/Monitor.propanthelinepropantheline and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.propofolpropofol and amoxapine both increase sedation. Use Caution/Monitor.propylhexedrineamoxapine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.protriptylineamoxapine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine